Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

rex medical ltd - efavirenz 600mg - film coated tablet - 600 mg - active: efavirenz 600mg excipient: lactose monohydrate magnesium stearate opadry yellow 03b52570 povidone pregelatinised maize starch sodium starch glycolate - efavirnez is indicated in antiviral combination treatment of hiv-1 infected adults, adolescents and children.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

viatris limited - efavirenz 600mg (varied based on 100 % assay) - film coated tablet - 600 mg - active: efavirenz 600mg (varied based on 100 % assay) excipient: colloidal silicon dioxide croscarmellose sodium hyprolose instacoat universal yellow ice-u-0144 lactose monohydrate magnesium stearate microcrystalline cellulose - antiviral combination treatment of hiv-1 infected adults, adolescents and children

Kanada - engleski - Health Canada

mylan pharmaceuticals ulc - efavirenz - tablet - 600mg - efavirenz 600mg - nonnucleoside reverse transcriptase inhibitors

Kanada - engleski - Health Canada

teva canada limited - efavirenz - tablet - 600mg - efavirenz 600mg - nonnucleoside reverse transcriptase inhibitors

Kanada - engleski - Health Canada

auro pharma inc - efavirenz - tablet - 600mg - efavirenz 600mg - nonnucleoside reverse transcriptase inhibitors

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

doh central pharmacy - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. for some drugs, competition for cyp3a by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (e.g., cardiac arrhythmias, prolonged sedation, or respiratory depression). drugs that are contraindicated with atripla are listed in table 1. pregnancy category d [see warnings and precautions (5.8)] the centers for disease control and prevention recommend that hiv-1 infected mothers not breast-feed their infants to avoid risking postnatal transmission of hiv-1. studies in rats have demonstrated that both efavirenz and tenofovir are secreted in milk. it is n

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

gilead sciences, llc - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg. - atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla [see warnings and precautions (5.2)] . - atripla is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see drug interactions (7.3) and clinical pharmacology (12.3)]. antiretroviral pregnancy registry there is a pregnancy exposure registry that monitors pregnancy outcomes in adults and adolescents exposed to atripla during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at (800) 258-4263. risk summary there are retrospective case reports of neural tube defects in infants whose mothers were e

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

gilead sciences, inc. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla™ is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg. - atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla [see warnings and precautions (5.2)]. - atripla is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see drug interactions (7.3) and clinical pharmacology (12.3)]. antiretroviral pregnancy registry there is a pregnancy exposure registry that monitors pregnancy outcomes in adults and adolescents exposed to atripla during pregnancy. healthcare providers are encouraged to register patients who become pregnant on the worldwide web at www.apregistry.com/. risk summary there are retrospective case reports of neural tube defects in infants whose mothers were exposed to efv-conta

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

physicians total care, inc. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. for some drugs, competition for cyp3a by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (e.g., cardiac arrhythmias, prolonged sedation, or respiratory depression). drugs that are contraindicated with atripla are listed in table 1. pregnancy category d [see warnings and precautions (5.8)] antiretroviral pregnancy registry: to monitor fetal outcomes of pregnant women, an antiretroviral pregnancy registry has been established. physicians are encouraged to register patients who become pregnant by cal

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

remedyrepack inc. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla ® is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg. - atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla [see warnings and precautions (5.2)] . - atripla is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see drug interactions (7.3) and clinical pharmacology (12.3)]. antiretroviral pregnancy registry there is a pregnancy exposure registry that monitors pregnancy outcomes in adults and adolescents exposed to atripla during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at (8